FDG-PET/CT finding of high uptake in pulmonary alveolar microlithiasis

Kimiteru Ito1, Kazuo Kubota, Masashi Yukihiro

  • 1Department of Nuclear Medicine, International Medical Center of Japan, 1-21-1 Toyama, Tokyo 162-8655, Japan. itoukimiteru@yahoo.co.jp

Annals of Nuclear Medicine
|September 19, 2007
PubMed

Insights

Pulmonary alveolar microlithiasis (PAM) involves lung calcification. This rare disease showed abnormal 18F-fluorodeoxyglucose (FDG) accumulation in the lungs, potentially linked to its underlying causes.

Area of Science:

  • Pulmonology
  • Nuclear Medicine
  • Radiology

Background:

  • Pulmonary alveolar microlithiasis (PAM) is a rare interstitial lung disease.
  • Characterized by diffuse intra-alveolar accumulation of calcified particles.
  • Often presents with progressive dyspnea and diffuse lung opacities.

Observation:

  • A 55-year-old male with a 25-year history of PAM presented with worsening dyspnea.
  • High-resolution CT showed extensive calcifications with minimal aeration.
  • FDG-PET/CT revealed significant abnormal 18F-fluorodeoxyglucose uptake in both lungs.

Findings:

  • Maximal standardized uptake value (SUVmax) of 7.3 for FDG.
  • Elevated FDG uptake was predominantly noted in lung regions spared from calcification.
  • Autopsy showed no significant inflammatory changes, despite high FDG uptake.

Implications:

  • Suggests a potential link between enhanced pulmonary FDG uptake and PAM pathophysiology.
  • Highlights the utility of FDG-PET/CT in evaluating rare lung diseases.
  • Warrants further investigation into metabolic changes in PAM.